U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06943950) titled 'A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis' on April 17.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Moderate to Severe Plaque Psoriasis
Intervention:
DRUG: SYHX1901
Administered orally, once daily (QD)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....